Dimensional Fund Advisors LP Has $216.77 Million Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Dimensional Fund Advisors LP boosted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 6.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,900,987 shares of the company's stock after acquiring an additional 1,074,274 shares during the period. Dimensional Fund Advisors LP owned approximately 3.62% of Elanco Animal Health worth $216,774,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB bought a new stake in Elanco Animal Health during the third quarter worth about $35,000. Jones Financial Companies Lllp lifted its stake in shares of Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after purchasing an additional 2,059 shares during the period. SRS Capital Advisors Inc. raised its position in shares of Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after acquiring an additional 3,411 shares during the period. MRP Capital Investments LLC acquired a new position in shares of Elanco Animal Health in the 4th quarter valued at $61,000. Finally, Blue Trust Inc. increased its holdings in shares of Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after acquiring an additional 1,894 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ELAN shares. UBS Group reduced their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Piper Sandler cut their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Stifel Nicolaus decreased their price target on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Morgan Stanley cut their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Finally, Barclays decreased their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $14.67.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were acquired at an average cost of $10.90 per share, with a total value of $109,000.00. Following the transaction, the director now owns 101,459 shares of the company's stock, valued at $1,105,903.10. The trade was a 10.93 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.89% of the stock is currently owned by company insiders.

Elanco Animal Health Trading Up 4.9 %

Shares of ELAN stock opened at $8.90 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock has a market capitalization of $4.42 billion, a price-to-earnings ratio of 22.24, a PEG ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $18.80. The company's fifty day simple moving average is $10.15 and its two-hundred day simple moving average is $11.74.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the firm earned $0.08 earnings per share. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.